[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"scabies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:scabies":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,70,96,126,158,185,207],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":40,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100631921","early-detection-and-ai-based-management-of-skin-related-neglected-tropical-diseases-in-sub-saharan-africa-by-frontline-health-workers-100631921",false,"NCT07506967","Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers","Early Detection and Management of SKIN-related negleCted Tropical Diseases Using Artificial Intelligence in Sub-saharan afRica (SkincAIr)","SkincAIr","1. Frontline Health Workers (FHWs) Age Group\n\n   * Age Range: 18 years and above o Justification: FHWs must be adults, legally eligible to provide healthcare services and consent to participate in the study Sex Distribution\n   * Male and Female FHWs o Justification: Both male and female FHWs will be included to reflect the actual workforce distribution and to ensure generalizability of the results across genders.\n\n   Inclusion criteria for FHWs:\n   1. Professional Role:\n\n      o Must be working as a FHW at one of the selected health centers at the time of the validation study.\n\n      ▪ Justification: The study aims to assess the diagnostic performance of those directly involved in primary patient care in the targeted settings.\n   2. Willingness to Participate:\n\n      o Willing to provide written informed consent to participate in the study.\n\n      ▪ Justification: Ethical standards require voluntary participation with informed consent.\n   3. Smartphone Usage:\n\n      o Willing and able to use a smartphone during the study.\n\n      ▪ Justification: The SkincAIr app is smartphone-based; therefore, FHWs must be willing to use and have access to such devices.\n   4. No Specialized Dermatology Training:\n\n      * FHWs without specialised training in dermatology or extensive experience in skin disease diagnosis.\n\n        * Justification: The study aims to evaluate the app's effectiveness among generalist healthcare workers who would benefit most from diagnostic support tools.\n\n   Exclusion criteria for FHWs:\n\n   1\\. Prior Specialised Training in dermatology:\n\n   o FHWs with formal education or extensive experience in dermatology.\n   * Justification: Including specialists could skew results, as their baseline diagnostic accuracy may already be high, reducing the observable impact of the app.\n\n     2\\. Refusal or Inability to Consent:\n     * FHWs unwilling or unable to provide written informed consent.\n   * Justification: Ethical compliance requires informed consent for participation. 3. Inability to Use the App: o FHWs unable to use a smartphone due to technical limitations, physical impairments, or lack of familiarity with the technology.\n   * Justification: Effective use of the app is essential for the intervention; inability to use it would prevent meaningful participation.\n2. Patients with Skin complaints Size\n\n   ● Total Patients: \\~750 patients Age Group\n\n   ● All Age Groups:\n\n   o Justification: Skin-NTDs affect individuals of all ages; including all age groups enhances the generalizability of the findings and assesses the app's effectiveness across the lifespan.\n\n   Sex Distribution\n   * Male and Female Patients\n   * Justification: Both sexes are included to capture the full spectrum of the disease burden and ensure the app's diagnostic accuracy is effective regardless of sex.\n\n   Inclusion Criteria for Patients with Skin complaints:\n\n   1\\. Presenting with Skin Complaints:\n\n   o Patients presenting to participating health centres with symptoms suggestive of skin-NTDs (e.g., visible skin lesions, nodules, ulcers) but have not been diagnosed by a specialist for that specific skin condition.\n   * Justification: The study aims to evaluate the app's effectiveness in real-world conditions, including all patients with potential skin-NTDs 2. Willingness to Participate: o Patients (or guardians, in the case of minors) willing to provide written informed consent for participation.\n   * Justification: Ethical standards require informed consent from patients or their legal guardians.\n\n     3\\. Ability to Comply with Study Procedures:\n\n     o Patients are able to follow study instructions and attend necessary follow-up appointments.\n   * Justification: Ensures complete data collection and accurate assessment of outcomes.\n\n     4\\. Patients with Co-morbid conditions:\n   * Justification: Immunosuppression that occurs in some comorbid conditions e.g. HIV\u002FAIDS or severe malnutrition can reveal the Skin disease and can affect both the clinical progression and even severity of the Skin NTD. This also includes patients with multiple skin-NTDs.\n\n   Exclusion Criteria for Patients with Skin complaints:\n   1. Refusal or Inability to Consent:\n\n      o Patients (or guardians) unwilling or unable to provide written informed consent.\n\n      ▪ Justification: Ethical compliance requires informed consent for participation.\n   2. Non-Skin-Related Complaints:\n\n      o Patients presenting with complaints unrelated to skin conditions.\n\n      ▪ Justification: The study focuses on skin-NTDs; including unrelated cases would not contribute to the study objectives.\n   3. Previous Participation in the Study:\n\n      o Patients who have already participated in the study.\n\n      ▪ Justification: To avoid duplicate data and potential bias in outcomes.\n\n      Additional Considerations:\n\n      Diversity and Representation ● Geographical Diversity:\n\n      o Including health centres from different regions within each country ensures that the findings are representative of various settings (urban, peri-urban, rural).\n\n      ● Cultural and Socioeconomic Factors:\n\n      o The study acknowledges that cultural beliefs and socioeconomic status may influence healthcare-seeking behaviour and disease presentation. By including a diverse patient population, the study aims to capture these variations.\n\n      Ethical Justification ● Inclusivity:\n      * Including all age groups and both sexes aligns with ethical principles of justice and fairness, ensuring that the benefits of the research are accessible to all segments of the population.\n\n        * Vulnerable Populations:\n      * While including minors and potentially vulnerable adults, the study will implement additional safeguards to protect their rights and well-being, following ethical guidelines and obtaining consent from guardians when necessary.","ALL","0 Years",{"count":20,"type":21},2420,"ESTIMATED","INTERVENTIONAL",[24],"NA","Skin-related Neglected Tropical Diseases (Skin NTDs) affect about 1.8 billion people worldwide, particularly in poor and rural communities where healthcare access is limited. Many people rely on frontline health workers (FHWs) for treatment, but these workers often lack specialized training in skin diseases, making diagnosis difficult. To address this challenge, the SkincAIr project is testing whether a mobile app powered by artificial intelligence (AI) can help FHWs improve their ability to detect Skin NTDs. The study will be conducted in two arms. In the first clinical image data collection arm (36 months), dermatologists in 5 countries (Kenya, Ethiopia, Senegal, Democratic Republic of Congo and Nigeria) will collect images of skin NTD and other skin conditions that will be used for development and training of the AI model within the SkincAIr app before it is tested among FHWs. The second validation study arm will take place in 3 countries (Kenya, Ethiopia and Senegal), and will involve 50 FHWs and around 750 patients in each country over 24 months. During the first 12 months (Phase A), FHWs will diagnose patients using standard methods without the app, establishing baseline performance on key indicators including diagnostic accuracy, time to diagnosis, referral patterns, and cost implications of improved primary-level diagnosis. For the following 6 months (Phase B), FHWs will use the SkincAIr app with AI functionality activated to support diagnosis and enable real-time geolocated disease mapping and hotspot identification. In the final 6 months (Phase C), the app is withdrawn to assess whether FHWs retain their improved diagnostic skills. We will summarize the results using simple numbers and charts to show how often things happen and what the average results look like. Researchers will evaluate how well the app improves diagnosis by FHWs and whether FHWs retain their improved skills even after AI support is removed, by comparing their results with those of a skin specialist (dermatologist). Interviews and group discussions will be recorded, written down, organized into key ideas, and carefully reviewed using a computer program to understand the main themes. Study findings will be shared with National Ministries of Health, presented at local and international conferences, and reported to relevant institutional and regulatory authorities. If successful, this AI tool could boost early detection of skin diseases, enhance disease tracking, and improve healthcare in underserved areas.",[27,28,29,30,31,32,33,34,35,36,37,38,39],"Skin and Connective Tissue Diseases","Neglected Tropical Diseases","Leprosy","Buruli Ulcer","Cutaneous Leishmaniasis","Scabies","Mycetoma","Lymphatic Filariasis","Onchocerciasis","Tungiasis","Post Kala-Azar Dermal Leishmaniasis","Yaws","Podoconiosis",[41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56],"Skin-related neglected tropical diseases","Artificial Intelligence","Mobile Health","mHealth","Frontline Health Workers","Diagnostic Accuracy","Sub-Saharan Africa","Skin NTDs","Digital Health","AI Diagnostic Tool","Capacity Building","Kenya","Ethiopia","Senegal","Nigeria","Democratic Republic of the Congo","NOT_YET_RECRUITING","2026-03-27",{"date":60,"type":61},"2026-04-02","ACTUAL",{"date":63,"type":21},"2026-05-01",{"date":65,"type":21},"2030-05-31",{"name":67,"class":68},"Kenya Medical Research Institute","OTHER",5,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":95},"100611980","early-phase-1-comparison-of-permethrin-based-treatment-strategies-against-scabies-in-infants-and-young-children-100611980","NCT07247630","Comparison of Permethrin-Based Treatment Strategies Against Scabies in Infants and Young Children","Inclusion Criteria:\n\n* 1 month to 4 years age.\n* Both gender\n* Scabies as defined in operational definition\n\nExclusion Criteria:\n\n* • Drug sensitivity test results for hypersensitivity to permethrin\n\n  * Having renal or hepatic impairment.\n  * Individuals with additional long-term skin and systemic disorders (such as diabetes, hypertension, asthma, epilepsy, acne, psoriasis)","1 Month","4 Years",{"count":79,"type":21},68,[81],"EARLY_PHASE1","To compare the efficacy of different permethrin-based therapies for scabies infestations in infants and young children.",[32],[85],"Permethrin based treatment strategies","2026-02-01",{"date":88,"type":61},"2026-02-03",{"date":90,"type":21},"2026-01-15",{"date":92,"type":21},"2026-06-15",{"name":94,"class":68},"College of Physicians and Surgeons Pakistan",1,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":17,"minAge":105,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":95},"100604147","phase-4-moxidectin-versus-ivermectin-as-mass-drug-administration-for-the-control-of-onchocerciasis-and-other-neglected-tropical-diseases-100604147","NCT07145736","Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases","Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases: A Cluster-randomised Trial","EKAIO","Inclusion Criteria:\n\n* Male or female children and adults\n* Residents in the villages selected for MDA treatment\n\nExclusion Criteria:\n\n* Arm 1 (ivermectin): children under the age of 5 and\u002For under 90 cm of height\n* Arm 2 (moxidectin): children under the age of 12 years (who will receive ivermectin if they are at least 90 cm in height\u002F5 years of age and above).\n* Arm 1 (ivermectin): Women breast-feeding babies under 45 days of age\n* Arm 2 (moxidectin): All breastfeeding women (who will be offered ivermectin if their infants is at least 45 days old)\n* Know allergy to ivermectin or moxidectin\n* Attending other clinical trials during the study\n* Pregnant\n* Arm 2 (moxidectin): Women planning to become pregnant in the 3 months post-treatment\n* Refusal to receive one or both study drugs, i.e. participants in villages allocated to receive moxidectin who refuse to receive moxidectin will be given the option to receive ivermectin; if they refuse to receive both drugs they will be excluded from the MDA altogether\n* Has an illness that makes them too sick or weak to get out of bed\n* Currently hospitalized",true,"5 Years",{"count":107,"type":21},52000,[109],"PHASE4","This clinical trial compares two treatments - ivermectin and moxidectin - to learn which is better at reducing the proportion of people with onchocerciasis (river blindness) when given through mass drug administration (MDA) in Angola. Both drugs are approved by the United States Food and Drug Administration (FDA) to treat this disease. The study also explores how these treatments affect other infections common in the region, including intestinal worms (soil-transmitted helminths) and scabies.\n\nThe trial aims to answer the following key questions:\n\n* How do moxidectin and ivermectin compare in reducing the prevalence (how common the disease is) and intensity (amount of parasites per person) of onchocerciasis in the community?\n* Do the treatments differ in their effect on the prevalence and intensity of soil-transmitted helminths and the prevalence of scabies?\n* Does moxidectin reduce transmission of onchocerciasis more effectively than ivermectin, based on genetic testing of parasites in people and lab testing of the blackflies that carry the infection?\n* How many more years of treatment would be needed to reach elimination with each drug, based on mathematical disease modelling?\n* How do communities feel about receiving moxidectin versus ivermectin, and what factors help or make it harder to carry out MDA programs with moxidectin versus ivermectin?\n\nThe study takes place in Bié Province, Angola, and involves 20 groups of villages randomly assigned to receive either moxidectin or ivermectin once a year for four years. Prior to every round of MDA, researchers will collect skin, stool and blood samples from a sample of the people living in the study area. We believe the results will help guide global policy on the use of moxidectin in efforts to eliminate onchocerciasis and control related diseases.",[35,112,113,114,32],"Ascaris Lumbricoides Infection","Trichuris Trichiura; Infection","Hookworm Infections","RECRUITING","2025-11-18",{"date":118,"type":61},"2025-11-21",{"date":120,"type":61},"2025-08-04",{"date":122,"type":21},"2029-06-30",{"name":124,"class":125},"Kirby Institute","OTHER_GOV",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":104,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":95},"100605196","phase-3-better-options-for-lymphatic-filariasis-treatment-100605196","NCT07159373","Better Options for Lymphatic Filariasis Treatment","Safety and Efficacy Trial of Mass Drug Administration With Moxidectin Versus Ivermectin in Combination With Diethylcarbamazine and Albendazole for Lymphatic Filariasis, Scabies, and Strongyloidiasis in Fiji","BOLT","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent.\n2. Resident in one of the study locations.\n\nExclusion Criteria:\n\nThere are no exclusion criteria to participation in the study.\n\nTreatment Exclusion Criteria:\n\nParticipants are ineligible to receive the treatment regimen allocated to their village if they meet any of the following criteria:\n\n1. Severe illness (any illness that is severe enough to interfere with activities of daily living);\n2. Known or suspected allergy to ivermectin, moxidectin, diethylcarbamazine or albendazole;\n3. Pregnant;\n4. Breastfeeding a baby within 7 days of birth;\n5. Age \\\u003C 4 years for villages randomised to moxidectin, diethylcarbamazine, and albendazole (MoxDA); or\n6. Age \\\u003C 2 years or weight \\\u003C 15 kg for villages randomized to ivermectin, diethylcarbamazine and albendazole (IDA).",{"count":135,"type":21},5100,[137],"PHASE3","The goal of this clinical trial is to learn if mass drug administration with moxidectin in combination with diethylcarbamazine, and albendazole (MoxDA) can treat lymphatic filariasis, scabies and strongyloidiasis in children and adults living in communities where these diseases are common. The main questions it aims to answer are:\n\n1. Does MoxDA clear infection in people with lymphatic filariasis ?\n2. Does MoxDA cause any medical problems in infected and uninfected people?\n\nResearchers will compare MoxDA with ivermectin given together with diethylcarbamazine and albendazole (IDA) to see if it works better to clear infection and does not cause any more medical problems.\n\nParticipants will:\n\n1. Be tested to see if they are infected with the parasites that cause lymphatic filariasis, scabies and strongyloidiasis\n2. Take 3 single doses of MoxDA or IDA, 12 months apart\n3. Visit their village centre once or twice in the 1 week after each treatment for safety checkups",[34,32,140],"Strongyloidiasis",[142,143,144,145,32,140,146,147,148],"Moxidectin","Ivermectin","Mass drug administration","Lymphatic filariasis","Cluster-randomized","Diethylcarbamazine","Albendazole","2025-09-03",{"date":151,"type":61},"2025-09-08",{"date":153,"type":21},"2026-03",{"date":155,"type":21},"2028-06",{"name":157,"class":68},"Medicines Development for Global Health",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":166,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":170,"briefSummary":172,"conditions":173,"keywords":174,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":95},"100585020","phase-2-comparison-of-permethrin-and-ivermectin-in-children-greater-than-6-yrs-age-for-treatment-of-scabies-100585020","NCT06896929","Comparison of Permethrin and Ivermectin in Children Greater Than 6 Yrs Age for Treatment of Scabies","Comparison of Topical Permethrin 1 Day Verses 2 Day Application Versus Oral Ivermectin for Treatment of Scabies in Children Greater Than 6 Yrs of Age","not existed","Inclusion Criteria:\n\n* Age 6-15\n* Both genders\n* Diagnosed with scabies (as per operational definition)\n\nExclusion Criteria:\n\n* Children with recurrent scabies on medical record\n* Known allergy to ivermectin or permethrin.\n* Widespread eczema or impetigo.\n* Liver dysfunction or renal failure","6 Years","15 Years",{"count":169,"type":21},90,[171],"PHASE2","Scabies is highly contagious,pruritic infestation of skin.Various treatment modalities have been used but search for ideal scabicide is ongoing.we wnt to coduct this study to compare the outcome of permethrin verses ivermectin in children for treatment of scabies .This randomized clinical trial will be done in children hospital lahore for 12 months.Sample size of 90 cases;30 in each group will be included through non probability consecutive sampling.Then patient will be randomly divided into 3 groups.In group A patient will be given 5% permethrin topical application to whole body single application. In Group B ,patients will be given topical permethrin for twice application 24 hrs appart ,In group C patients will be given Tablet Ivermectin single dose 200microgram\u002Fkg.Then patients will be examined after 2 weeks and 4 weeks for no of lesions and pruritis and cure will be labeled.All this information will be recorded on performa .Data will be entered and analysed by using SPSS version 26.Three groups will be compared for cure by using chi-square test.P value less than and equal to 0.05 will be considered as significant.",[32],[175],"Comparison of permethrin and ivermectin in scabies","2025-04-17",{"date":178,"type":61},"2025-04-20",{"date":180,"type":21},"2025-05-01",{"date":182,"type":21},"2026-04-01",{"name":184,"class":68},"Children Hospital and Institute of Child Health, Lahore",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":104,"sex":17,"minAge":192,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":95},"100558089","early-phase-1-sensitivity-of-self-collected-skin-sampling-for-scabies-a-pilot-study-100558089","NCT06546579","Sensitivity of Self-collected Skin Sampling for Scabies: a Pilot Study","SCRAPE","Inclusion Criteria:\n\n* 18 years or older\n* Have either suspected scabies, clinical scabies or confirmed scabies (see table 1)\n* Providing informed consent (IC)\n\nExclusion Criteria:\n\n* Individuals not speaking or understanding the Dutch or English language.\n* Individuals who have been diagnosed with scabies in the last six weeks and had started treatment.\n* Individuals who have used ivermectin for other diagnoses than scabies in the last six weeks.\n* Individuals younger than 18 years.\n* Individuals with immunosuppressive conditions (see appendix A).\n* Any other condition, finding or situation which, in the opinion of the investigator, may significantly increase the risk to the individual because of participation in the study, affect the ability of the individual to participate in the study or impair interpretation of the study data.","18 Years",{"count":194,"type":21},144,[81],"In this cross-sectional diagnostic study, healthy adults aged 18 and older with suspected, clinical, or confirmed scabies will be recruited. The objective is to determine if the sensitivity of self-collected skin samples for scabies diagnosis is non-inferior to professional sampling, and compare the sensitivity and specificity of the polymerase chain reaction assay (PCR) versus microscopy.",[32],"2024-08-06",{"date":200,"type":61},"2024-08-09",{"date":202,"type":21},"2024-08-21",{"date":204,"type":21},"2025-06",{"name":206,"class":68},"Radboud University Medical Center",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":17,"minAge":215,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":22,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":4},"100545326","phase-3-therapy-for-scabies-with-two-differently-concentrated-permethrin-creams-100545326","NCT06380452","Therapy for Scabies With Two Differently Concentrated Permethrin Creams","Phase III Multicenter, Prospective, Randomized, Double-blind Study Comparing the Efficacy and Safety of Therapy for Scabies With Two Differently Concentrated Permethrin Creams.","SKABUP","Inclusion Criteria:\n\n* Confirmed acute scabies disease: Detection of mites and\u002For mite nymphs and\u002For mite larvae, by reflected light microscopy or light microscopy of skin samples, at scabies-typical predilection sites\n* Age between 2 years and 85 years\n* Written informed consent of the study participant (if of legal age) or all legal guardians (for underage study participants \\\u003C 12 years) or all legal guardians and the study participant (for underage study participants ≥ 12 years)\n* Practicable application of the trial medication by trained specialist staff at the trial site\n\nExclusion Criteria:\n\n* Pre-treatment with antiscabiosa in the last 14 days\n* Combined antiscabial treatment (i.e. simultaneous\u002Fsimultaneous topical and systemic scabies treatment with medication) in the last 3 months\n* Known intolerance to permethrin, other pyrethroids, chrysanthemums or any of the other ingredients of the study medication\n* Scabies crustosa\n* Impetiginization\u002Feczematization requiring inpatient treatment\n* Body weight \\> 120 kg\n* Pregnancy, breastfeeding\n* Clinically relevant immunodeficiency (of any kind, including extensive local therapy (\\>20% body surface) with corticosteroids \\> 2 weeks in the last 4 weeks or ≥ 10 mg prednisolone equivalent \\>7 days in the last 4 weeks - even without signs of scabies crustosa)\n* Other serious illnesses which, in the opinion of the investigator, prevent the patient from participating in the study\n* Planned systemic use of corticosteroids\n* Planned or previous (last 4 weeks) use of systemic or cutaneous non-steroidal immunosuppressants\n* Apparent unreliability or unwillingness to cooperate\n* Inability to understand and comply with study instructions\n* Known alcohol, medication or drug dependence\n* Placement in a facility where people live together for long periods of time, are cared for or receive medical care, and where close skin-to-skin contact is common, or placement in an institution ordered by a court\u002Fauthority\n* 5 or more close contacts (persons with close, extensive skin-to-skin contact with the scabies patient for more than 5-10 minutes)\n* Close contact person who refuses scabies treatment or for whom treatment is not possible\n* Dependence on sponsor or investigator\n* Previous participation in a clinical trial in the last 30 days or in the same clinical trial","2 Years","85 Years",{"count":218,"type":21},220,[137],"The multi-center, prospective, randomized, double-blind phase III clinical trial will primarily investigate the efficacy and safety of treatment of scabies with Permethrin Cream 5% (approved drug InfectoScab 5% Cream) in direct comparison with Permethrin Cream 10%.\n\nThe trial participants will be randomly assigned and blinded to either Permethrin Cream 5% or Permethrin Cream 10%.",[32],"2024-04-22",{"date":224,"type":61},"2024-04-23",{"date":226,"type":21},"2024-05",{"date":228,"type":21},"2028-12",{"name":230,"class":231},"Infectopharm Arzneimittel GmbH","INDUSTRY"]